Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.92
NAS:ALKS's Cash to Debt is ranked lower than
71% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:ALKS: 1.92 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ALKS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 1.56 Max: No Debt
Current: 1.92
Equity to Asset 0.71
NAS:ALKS's Equity to Asset is ranked higher than
54% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ALKS: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ALKS' s Equity to Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.63 Max: 0.9
Current: 0.71
-0.15
0.9
F-Score: 3
Z-Score: 9.90
M-Score: -2.81
WACC vs ROIC
15.61%
-24.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -36.27
NAS:ALKS's Operating margin (%) is ranked higher than
59% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:ALKS: -36.27 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ALKS' s Operating margin (%) Range Over the Past 10 Years
Min: -36.27  Med: -7.62 Max: 41.29
Current: -36.27
-36.27
41.29
Net-margin (%) -36.92
NAS:ALKS's Net-margin (%) is ranked higher than
58% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:ALKS: -36.92 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ALKS' s Net-margin (%) Range Over the Past 10 Years
Min: -36.92  Med: -1.29 Max: 69.37
Current: -36.92
-36.92
69.37
ROE (%) -20.06
NAS:ALKS's ROE (%) is ranked higher than
62% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:ALKS: -20.06 )
Ranked among companies with meaningful ROE (%) only.
NAS:ALKS' s ROE (%) Range Over the Past 10 Years
Min: -20.06  Med: 0.11 Max: 65.64
Current: -20.06
-20.06
65.64
ROA (%) -14.22
NAS:ALKS's ROA (%) is ranked higher than
63% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:ALKS: -14.22 )
Ranked among companies with meaningful ROA (%) only.
NAS:ALKS' s ROA (%) Range Over the Past 10 Years
Min: -14.22  Med: -0.42 Max: 27.26
Current: -14.22
-14.22
27.26
ROC (Joel Greenblatt) (%) -75.88
NAS:ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:ALKS: -75.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ALKS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -75.88  Med: 6.41 Max: 131.93
Current: -75.88
-75.88
131.93
Revenue Growth (3Y)(%) 7.40
NAS:ALKS's Revenue Growth (3Y)(%) is ranked higher than
56% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:ALKS: 7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ALKS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.1  Med: 8.6 Max: 69.6
Current: 7.4
-22.1
69.6
EBITDA Growth (3Y)(%) 35.80
NAS:ALKS's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:ALKS: 35.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ALKS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.3  Med: 11.5 Max: 85.6
Current: 35.8
-1.3
85.6
EPS Growth (3Y)(%) 15.40
NAS:ALKS's EPS Growth (3Y)(%) is ranked higher than
73% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:ALKS: 15.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ALKS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.1  Med: 15.85 Max: 224
Current: 15.4
-24.1
224
» NAS:ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ALKS Guru Trades in Q4 2015

Paul Tudor Jones 6,782 sh (New)
Jim Simons 26,286 sh (New)
Ken Fisher 120,327 sh (+0.34%)
Jeff Auxier 26,851 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Vanguard Health Care Fund 6,851,996 sh (-0.40%)
Pioneer Investments 208,726 sh (-30.52%)
George Soros 3,400 sh (-56.96%)
» More
Q1 2016

ALKS Guru Trades in Q1 2016

Paul Tudor Jones 21,964 sh (+223.86%)
Pioneer Investments 345,537 sh (+65.55%)
Vanguard Health Care Fund 8,603,676 sh (+25.56%)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Ken Fisher 120,297 sh (-0.02%)
Jeff Auxier 26,751 sh (-0.37%)
» More
Q2 2016

ALKS Guru Trades in Q2 2016

PRIMECAP Management 2,505,450 sh (New)
Ken Fisher 123,094 sh (+2.33%)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments 249,164 sh (-27.89%)
» More
Q3 2016

ALKS Guru Trades in Q3 2016

George Soros 4,600 sh (New)
PRIMECAP Management 3,153,560 sh (+25.87%)
Ken Fisher 129,607 sh (+5.29%)
Vanguard Health Care Fund 8,603,676 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,751 sh (unchged)
Pioneer Investments 155,087 sh (-37.76%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SGEN, OTCPK:NVZMF, NAS:TSRO, OTCPK:GMXAY, NAS:JAZZ, NAS:UTHR, NAS:IONS, OTCPK:UCBJY, NAS:EXEL, NAS:MDVN, OTCPK:GIKLY, NAS:ALNY, NAS:TECH, NYSE:XON, NAS:RARE, NAS:ACAD, NAS:CBPO, NAS:ICPT, OTCPK:BTGGF, NAS:GLPG » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.

Alkermes PLC is a biotechnology incorporated on May 4, 2011. The Company is engaged in developing, manufacturing and commercializing medicines to address unmet medical needs of patients in various therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders such as schizophrenia, depression, addiction and multiple sclerosis. The company is subject to the laws and regulations from the U.S. Foreign Corrupt Practices Act (FCPA).

Ratios

vs
industry
vs
history
Forward P/E 200.00
ALKS's Forward P/E is ranked lower than
98% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. ALKS: 200.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 7.49
ALKS's P/B is ranked lower than
76% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ALKS: 7.49 )
Ranked among companies with meaningful P/B only.
ALKS' s P/B Range Over the Past 10 Years
Min: 1.66  Med: 4.31 Max: 101.62
Current: 7.49
1.66
101.62
P/S 12.94
ALKS's P/S is ranked lower than
54% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. ALKS: 12.94 )
Ranked among companies with meaningful P/S only.
ALKS' s P/S Range Over the Past 10 Years
Min: 2.21  Med: 7.1 Max: 18.81
Current: 12.94
2.21
18.81
Current Ratio 4.24
ALKS's Current Ratio is ranked higher than
50% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ALKS: 4.24 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6 Max: 15.4
Current: 4.24
2.01
15.4
Quick Ratio 3.96
ALKS's Quick Ratio is ranked higher than
50% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. ALKS: 3.96 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.79 Max: 15.4
Current: 3.96
1.95
15.4
Days Inventory 123.95
ALKS's Days Inventory is ranked higher than
51% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. ALKS: 123.95 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 110.47 Max: 166.33
Current: 123.95
86.09
166.33
Days Sales Outstanding 93.15
ALKS's Days Sales Outstanding is ranked lower than
70% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. ALKS: 93.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 93.15
Current: 93.15
27.46
93.15
Days Payable 121.22
ALKS's Days Payable is ranked higher than
74% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ALKS: 121.22 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 561.6
Current: 121.22
39.15
561.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ALKS: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -9.5 Max: 2.1
Current: -5
-16.1
2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 171.38
ALKS's Price/Net Cash is ranked lower than
98% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. ALKS: 171.38 )
Ranked among companies with meaningful Price/Net Cash only.
ALKS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.39  Med: 20.95 Max: 171.38
Current: 171.38
3.39
171.38
Price/Net Current Asset Value 28.56
ALKS's Price/Net Current Asset Value is ranked lower than
89% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. ALKS: 28.56 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALKS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.39  Med: 16.88 Max: 343
Current: 28.56
2.39
343
Price/Tangible Book 11.29
ALKS's Price/Tangible Book is ranked lower than
81% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ALKS: 11.29 )
Ranked among companies with meaningful Price/Tangible Book only.
ALKS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 9.65 Max: 365.22
Current: 11.29
1.8
365.22
Price/Projected FCF 10.01
ALKS's Price/Projected FCF is ranked lower than
78% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. ALKS: 10.01 )
Ranked among companies with meaningful Price/Projected FCF only.
ALKS' s Price/Projected FCF Range Over the Past 10 Years
Min: 2  Med: 3.93 Max: 20.95
Current: 10.01
2
20.95
Price/Median PS Value 1.78
ALKS's Price/Median PS Value is ranked lower than
82% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ALKS: 1.78 )
Ranked among companies with meaningful Price/Median PS Value only.
ALKS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.63 Max: 14.41
Current: 1.78
0.42
14.41
Earnings Yield (Greenblatt) (%) -2.83
ALKS's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. ALKS: -2.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALKS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3  Med: 2.4 Max: 53.4
Current: -2.83
-3
53.4

More Statistics

Revenue (TTM) (Mil) $695.3
EPS (TTM) $ -1.69
Beta2.02
Short Percentage of Float6.96%
52-Week Range $27.14 - 80.71
Shares Outstanding (Mil)151.56

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 732 897 1,112
EPS ($) -0.32 0.28 0.86
EPS w/o NRI ($) -0.32 0.28 0.86
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in... Dec 05 2016
ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 02 2016
CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to... Nov 30 2016
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare... Nov 18 2016
Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election Nov 15 2016
Drug pricing pressure Nov 15 2016
ETF’s with exposure to Alkermes Plc : November 10, 2016 Nov 10 2016
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Nov 09 2016
Alkermes Plc :ALKS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 Nov 09 2016
ALKERMES PLC. Financials Nov 05 2016
Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact Nov 03 2016
ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use... Nov 03 2016
ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use... Nov 03 2016
ALKERMES Inspiration Grants™ Awarded to Support People Affected by Mental Health and Substance Use... Nov 03 2016
Edited Transcript of ALKS earnings conference call or presentation 2-Nov-16 12:30pm GMT Nov 02 2016
Alkermes reports 3Q loss Nov 02 2016
Alkermes reports 3Q loss Nov 02 2016
Alkermes plc Reports Third Quarter 2016 Financial Results Nov 02 2016
ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 02 2016
Q3 2016 Alkermes Plc Earnings Release - Before Market Open Nov 02 2016
Alkermes plc Reports Third Quarter 2016 Financial Results Nov 02 2016
Alkermes plc Reports Third Quarter 2016 Financial Results Nov 02 2016
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare... Nov 01 2016
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare... Nov 01 2016
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare... Nov 01 2016
Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More Nov 01 2016
Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On Oct 27 2016
Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Oct 26 2016
Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Oct 26 2016
Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Oct 26 2016
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for... Oct 20 2016
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for... Oct 20 2016
Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for... Oct 03 2016
Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for... Oct 03 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Sep 19 2016
Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and... Sep 12 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 06 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA®... Aug 08 2016
Alkermes reports 2Q loss Jul 28 2016
Alkermes plc Reports Second Quarter 2016 Financial Results Jul 28 2016
Alkermes plc Reports Second Quarter 2016 Financial Results Jul 28 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes’ Corporate Presentation to Be Webcast at the Goldman Sachs 37th Annual Global Healthcare... Jun 01 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Appoints Nancy Snyderman, M.D., to Board of Directors May 26 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 May 25 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 09 2016
Alkermes reports 4Q loss Feb 25 2016
Alkermes reports 3Q loss Oct 29 2015
Alkermes reports 2Q loss Jul 30 2015
Alkermes reports 1Q loss Apr 30 2015
Alkermes beats Street 4Q forecasts Feb 24 2015
Alkermes reports 3Q loss Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)